NEW YORK (GenomeWeb) – Insilico Medicine announced today that it has partnered with Singapore-based molecular diagnostics firm Asia Genomics to develop biomarkers of aging and longevity for Asian populations.

Under the terms of the deal, the companies will identify personalized aging-related biomarkers based on individuals' age-annotated genomic and transcriptomic data. They also aim to develop an age-predicting algorithm that will be incorporated into multiple deep neural networks trained and tested on Asian blood chemistry samples.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.